Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 6—June 2015

Additional Drug Resistance of Multidrug-Resistant Tuberculosis in Patients in 9 Countries

Ekaterina V. KurbatovaComments to Author , Tracy Dalton, Julia Ershova, Thelma E. Tupasi, Janice Campos Caoili, Martie L. van der Walt, Charlotte L. Kvasnovsky, Martin Yagui, Jaime Bayona, Carmen Contreras, Vaira Leimane, Laura E. Via, HeeJin Kim, Somsak Akksilp, Boris Y. Kazennyy, Grigory V. Volchenkov, Ruwen Jou, Kai Kliiman, Olga V. Demikhova, and J. Peter Cegielski
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.V. Kurbatova, T. Dalton, J. Ershova, J. Campos Caoili, C. Kvasnovsky, J.P. Cegielski); Tropical Disease Foundation, Manila, the Philippines (T. Tupasi, J. Campos Caoili); Medical Research Council, Pretoria, South Africa (M. Van Der Walt, C. Kvasnovsky); National Institute of Health, Lima, Peru (M. Yagui); Socios en Salud Sucursal Perú, Lima (J. Bayona, C. Contreras); Riga East University Hospital Centre of Tuberculosis and Lung Diseases, Riga, Latvia (V. Leimane); National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA (L.E. Via); University of Cape Town, Cape Town, South Africa (L.E. Via):; Korean Institute of TB, Seoul, South Korea (H. Kim); Ministry of Public Health, Bangkok, Thailand (S. Akksilp); Orel Oblast Tuberculosis Dispensary, Orel, Russia (B.Y. Kazennyy); Vladimir Oblast Tuberculosis Dispensary, Vladimir, Russia (G.V. Volchenkov); Taiwan Centers for Disease Control, Taipei, Taiwan (R. Jou); Tartu University Hospital, Tartu, Estonia (K. Kliiman); Russian Academy of Medical Sciences, Moscow, Russia (O.V. Demikhova)

Main Article

Table 1

Proportion of patients with multidrug-resistant tuberculosis who would have qualified for treatment with the short (9-month) regimen or with bedaquiline-containing regimen, 2005–2008*

Candidate regimen Country, no. patients (%)
Estonia, n = 24 Latvia, n = 89 Peru, n = 194 Philippines, n = 386 Russia, n = 96 South Africa, n = 281 South Korea, n = 96 Taiwan, n = 40 Thailand, n = 48 Total, N = 1,254
Short† 13 (54.2) 42 (47.2) 154 (79.4) 357 (92.5) 59 (61.5) 195 (69.4) 58 (60.4) 31 (77.5) 43 (89.6) 952 (75.9)
BDQ‡ 11 (45.8) 47 (52.8) 40 (20.6) 29 (7.5) 37 (38.5) 86 (30.6) 38 (39.6) 9 (22.5) 5 (10.4) 302 (24.1)

*Percentages show proportion of patients in cohort form each country who would be candidates for a particular regimen. BDQ, bedaquiline.
†Candidates for short regimen were patients without baseline resistance to fluoroquinolones and second-line injectable drugs.
‡Candidates for BDQ-containing regimen were patients with baseline resistance to fluoroquinolones or second-line injectable drugs.

Main Article

Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.